Compare JBS N.V. Class A Common Shares (JBS) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JBS N.V. Class A Common Shares vs Tempus AI — how do they compare? JBS N.V. Class A Common Shares trades at $13.02 (market cap $13.96B), while Tempus AI trades at $65.17 (market cap $12.40B). The key difference: JBS N.V. Class A Common Shares and Tempus AI are close in size by market cap, and JBS N.V. Class A Common Shares pays a 10.31% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold JBS N.V. Class A Common Shares for 0 Days and Tempus AI for 23 Days on average.
| JBS | TEM | |
|---|---|---|
Market Cap | $13.96B | $12.40B |
Volume | 5,326,589 | 6,036,503 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $18.42 | $92.45 |
52-Week Low | $10.86 | $41.55 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $34.93B | $13.03B |
Dividend Yield | 10.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
Tempus AI (TEM) trades at $68.22, up 0.34% on the day, with a bullish technical signal despite negative profitability. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent FDA clearance for its ECG-MR AI product and multiple data licensing agreements highlight ongoing business development. Revenue growth is projected from $1.27 billion in 2025 to $1.4 billion in 2026, though net losses persist.
The outlook is supported by strong analyst consensus (64% buy ratings) and a $72.60 price target, suggesting modest upside. Key risks include sustained negative cash flow from operations, high valuation multiples, and insider selling. Investment appeal hinges on the company's ability to translate top-line growth into profitability amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
